全文获取类型
收费全文 | 665314篇 |
免费 | 73216篇 |
国内免费 | 361篇 |
专业分类
738891篇 |
出版年
2016年 | 6957篇 |
2015年 | 9635篇 |
2014年 | 11385篇 |
2013年 | 16742篇 |
2012年 | 18388篇 |
2011年 | 18783篇 |
2010年 | 12829篇 |
2009年 | 11878篇 |
2008年 | 16866篇 |
2007年 | 17684篇 |
2006年 | 16723篇 |
2005年 | 16191篇 |
2004年 | 16068篇 |
2003年 | 15933篇 |
2002年 | 15479篇 |
2001年 | 26025篇 |
2000年 | 26144篇 |
1999年 | 21190篇 |
1998年 | 7914篇 |
1997年 | 8357篇 |
1996年 | 8087篇 |
1995年 | 7552篇 |
1994年 | 7468篇 |
1993年 | 7495篇 |
1992年 | 18802篇 |
1991年 | 18388篇 |
1990年 | 18295篇 |
1989年 | 18019篇 |
1988年 | 16920篇 |
1987年 | 16304篇 |
1986年 | 15193篇 |
1985年 | 15751篇 |
1984年 | 13167篇 |
1983年 | 11493篇 |
1982年 | 9003篇 |
1981年 | 8292篇 |
1980年 | 7706篇 |
1979年 | 12975篇 |
1978年 | 10156篇 |
1977年 | 9563篇 |
1976年 | 9246篇 |
1975年 | 10007篇 |
1974年 | 10950篇 |
1973年 | 10720篇 |
1972年 | 9982篇 |
1971年 | 9019篇 |
1970年 | 7884篇 |
1969年 | 7881篇 |
1968年 | 7268篇 |
1967年 | 6244篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
O Chisaka K Araki T Ochiya T Tsurimoto W Hiranyawasitte-Attatippaholkun N Yanaihara K Matsubara 《Gene》1987,60(2-3):183-189
A fused gene containing 94% of the hepatitis B virus (HBV) open reading frame X was expressed in Escherichia coli, and its 17-kDa product was purified by ion-exchange chromatography. Antibody elicited against the X-gene product reacted with materials proximal to the nuclear membrane of a human hepatoblastoma cell line producing HBV particles. No such reaction was observed with the same cell line that did not produce HBV particles. 相似文献
993.
N. Rocks C. Estrella G. Paulissen F. Quesada‐Calvo C. Gilles M. M. Guéders C. Crahay J.‐M. Foidart P. Gosset A. Noel D. D. Cataldo 《Cell proliferation》2008,41(6):988-1001
Abstract. Objectives: The ADAMs (a disintegrin and metalloproteinase) enzymes compose a family of membrane‐bound proteins characterized by their multi‐domain structure and ADAM‐12 expression is elevated in human non‐small cell lung cancers. The aim of this study was to investigate the roles played by ADAM‐12 in critical steps of bronchial cell transformation during carcinogenesis. Materials and methods: To assess the role of ADAM‐12 in tumorigenicity, BEAS‐2B cells were transfected with a plasmid encoding human full‐length ADAM‐12 cDNA, and then the effects of ADAM‐12 overexpression on cell behaviour were explored. Treatment of clones with heparin‐binding epidermal growth factor (EGF)‐like growth factor (HB‐EGF) neutralizing antibodies as well as an EGFR inhibitor allowed the dissection of mechanisms regulating cell proliferation and apoptosis. Results: Overexpression of ADAM‐12 in BEAS‐2B cells promoted cell proliferation. ADAM‐12 overexpressing clones produced higher quantities of HB‐EGF in their culture medium which may rely on membrane‐bound HB‐EGF shedding by ADAM‐12. Targeting HB‐EGF activity with a neutralizing antibody abrogated enhanced cell proliferation in the ADAM‐12 overexpressing clones. In sharp contrast, targeting of amphiregulin, EGF or transforming growth factor‐α failed to influence cell proliferation; moreover, ADAM‐12 transfectants were resistant to etoposide‐induced apoptosis and the use of a neutralizing antibody against HB‐EGF activity restored rates of apoptosis to be similar to controls.Conclusions: ADAM‐12 contributes to enhancing HB‐EGF shedding from plasma membranes leading to increased cell proliferation and reduced apoptosis in this bronchial epithelial cell line. 相似文献
994.
995.
Severe aortic valve stenosis (AVS) and mitral valve regurgitation (MVR) often coexist. Although a fully percutaneous treatment for the two conditions, by means of transcatheter aortic valve implantation (TAVI) followed by MitraClip, can be appealing in selected high-risk candidates, critical and strategical reasoning should be applied. In a 3-year period we have developed a single-centre experience of 14 patients who were managed with a staged percutaneous approach to treat severe AVS and MVR. The average interval from TAVI to MitraClip repair was 101 ± 12 days. Success for TAVI was 100% and 92.9% (13/14) for MitraClip. At late follow-up, 3 patients developed MVR 3+. Estimated 1?year survival was 66.5%. Freedom from 1?year endpoint (death, stroke, major bleeding, myocardial infarction, and cardiac re-hospitalisation) was 57.9%.In our view, a fully transcatheter approach for mitro-aortic pathology is feasible and should be performed only as a staged procedure in those patients that remain symptomatic, in spite of successful TAVI. It should be emphasised that although the periprocedural success rate is satisfactory, follow-up mortality and re-hospitalisation rates remain high, even at mid-term follow-up. This most probably results from the advanced clinical picture at time of referral for treatment. 相似文献
996.
997.
998.
999.
W. H. Inman 《BMJ (Clinical research ed.)》1994,309(6954):608-609
1000.